Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

ACTH Syndrome, Ectopic 4Cushing Syndrome 3Hypertension 2Adrenal Hyperplasia, Congenital 2Adrenal Cortex Neoplasms 1Acth-Independent Macronodular Adrenal Hyperplasia 1

Interventions

relacorilant 3pembrolizumab 3cabozantinib 2Mifepristone 2Corlux 2veliparib 1tariquidar 1olaparib 1lutetium Lu 177 dotatate 1fludarabine phosphate 1fludarabine 1Temozolomide 1Specimen Handling 1Pharmacogenomic Variants 1Pharmacogenomic Testing 1Osilodrostat 1Nivolumab 1Mesna 1Magnetic Resonance Spectroscopy 1Gefitinib 1Floxuridine 1Dexamethasone 1Cyclophosphamide 1Capecitabine 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adrenal Cortex Neoplasms × Osilodrostat × Clear all
NCT02468193 2020-05-06

Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome

Novartis

Phase 2 Completed
9 enrolled 22 charts

Acth-Independent Macronodular Adrenal Hyperplasia, ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Cushing Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡